BioStock: Immunicum gears up for second half of 2020

2020 has so far been a transition year for Immunicum. While continuing their progress with the Phase II MERECA study and Phase Ib/II ILIAD study, they have received RMAT designation from the FDA for their top drug candidate ilixadencel. Recently, the immuno-oncology company also received feedback from both the FDA and EMA to further support preparations of the next steps in development. BioStock spoke with Immunicum’s Interim CEO Alex Karlsson-Parra to look back at the year so far and see what is in the books for the rest of the year.

Read the full interview with Alex Karlsson-Parra at biostock.se:

https://www.biostock.se/en/immunicum-gears-up-for-second-half-of-2020-2/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se